Monday, December 29, 2014

Biomarkers For Early Cancer Diagnosis

Early detection of cancer greatly increases the chances for successful treatment. For early detection of cancer, better diagnostic and cancer management techniques are required.

Credit: © Thinkstock

Millions of deaths occur annually worldwide as a result of ovarian, endometrial, bladder and prostate cancers. Early diagnosis is a key factor to achieve treatment breakthrough and better patient outcomes.

The EU-funded PROTBIOFLUID project created a network to develop early cancer detection techniques and spread this knowledge in the medical community. Biofluids were studied to develop specific proteomic profiles that could act as biomarkers for cancer diagnosis.

From the very beginning, this project acted as a catalyst for organising a focused scientific network. This network includes leading research partners with desired complementary expertise.

Several strategies were defined for the identification of diagnostic markers in ovarian, endometrial and prostate cancers as well as prognostic markers in ovarian cancer. Researchers' finalised the optimisation phase for all the approaches and are currently performing in-depth study and data analysis. They characterised molecular events of myometrium infiltration in vitro and in vivo associated with ETV5 transcription factor, as this gene is upregulated in invasive cancers.

Tumour invasion in many types of cancer is triggered by epithelial-mesenchymal transition with the participation of E-cadherin, a transmembrane protein. Researchers observed that the relation between E-cadherin and its variant defines the prognostic value of the tumours. To evaluate future therapies, they developed prostate and endometrial animal models that can be followed-up in vivo to study the progression of the tumour. This tool permits in vivo monitoring to determine drug efficacy and characterise the role of the targets.

At the conclusion of the PROTBIOFLUID project, partners plan to create a framework for joint programs between their institutions. This nucleus of teams would form the core of a growing network working on developing innovative treatments for these deadly cancers.


Contacts and sources
CORDIS

Report Summary:  Periodic Report Summary 1 - PROTBIOFLUID (PROTEOMIC IDENTIFICATION OF BIOMARKERS IN BIOFLUIDS AND IN PRECLINICAL MODELS FOR THE EARLY DIAGNOSIS AND PROGNOSIS OF CANCER (PROT*BIO*FLUID))

No comments:

Post a Comment